Tuberculosis|omicsgroup|Journal Of Topical Diseases And Public Health

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Tuberculosis (TB) remains one of the world’s major health problems. It is estimated that 8.6 million people developed TB, and 1.3 million died from the disease in 2012. Because of the increased drug-resistance of the causative bacterium M. tuberculosis (Mtb), about a half of the multidrug-resistant tuberculosis (MDR-TB) patients were not successfully treated globally in 2010. Thus, it is urgent to identify novel therapeutic targets for developing drugs that can treat drug-susceptible and drug-resistant TB. Since Mtb is an intracellular pathogen mainly residing in macrophages, thus elucidating the mechanisms underlying Mtb-macrophage interactions is crucial to the development of Mtb-host interfaces-targeted therapeutics. M. tuberculosis and Macrophages: Co-existence and Co-evolution-Cui Hua Liu OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the dramatic effort of editorial board members. Journal of Tropical Diseases & Public Heath publishes original research articles, novel, and scientifically sound findings dealing with tropical diseases related to human health.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2021